



# 13<sup>th</sup>

## NSOO

March 1|3  
2024

### Friday 1st March

- 13.00-16.00 Registration  
16.00-16.20 **Opening:**  
Darjana Jovanovic, Zoran Radovanovic, Snezana Brkic,  
Lazar Popovic (Novi Sad, Serbia)
- 16.20-16.30 **How everything began?**  
Jean Pierre Lotz, Paris, France
- 16.30-18.30 **AROME Plenary Session,**  
Chairman: Semir Bešlija (Sarajevo), Nikola Milasevic (Podgorica),  
Olivera Ivanov (Novi Sad, Serbia)
- 16.30-17.00 **What we need from oncology science in next 20 years?**  
Joseph Gligorov, Paris, France
- 17.00-17.30 **How to de-escalate radiotherapy – doses, fields, toxicity?**  
Yazid Belkacemi, Paris, France
- 17.30-18.00 **Novelties in supportive and palliative care trials**  
Tomi Kovacevic, Novi Sad, Serbia
- 18.00-18.30 Discussion

● 18.30-19.15 SATELLITE SYMPOSIUM ASTRA ZENECA

### Saturday 2nd March

● 08.30-09.00 SATELLITE SYMPOSIUM MEDISON PHARMA

- 09.00-10.45 **NSOC School of Immunotherapy**  
Chairman: Bojan Zaric (Novi Sad), Suzana Matkovic (Belgrade),  
Maja Popovic (Novi Sad, Serbia)
- 09.00-09.20 **How to improve efficacy and patient selection for lung cancer immunotherapy: biomarkers, combos and more...**  
Marko Jakopovic, Zagreb, Croatia
- 09.20-09.40 **Optimal utility of CPI in Head and Neck Cancer**  
Coralie Prebet, Paris, France
- 09.40-10.00 **More than CPI in melanoma immunotherapy: vaccines, TILs, combos**  
Alice Indini, Milan, Italy
- 10.00-10.20 **CAR-T, bispecific antibodies and CPIs in the treatment of Lymphoma**  
Anna Sureda Balari, Barcelona, Spain
- 10.20-10.45 Discussion
- 10.45-11.15 Coffee Break

● 11.15-12.00 SATELLITE SYMPOSIUM MSD

● 12.00-12.45 SATELLITE SYMPOSIUM AMICUS

12.45-13.45 Lunch Break

### 13.45-15.30 Genito-Urinary Cancer Session

- Chairman: Timur Cerić (Sarajevo), Zoran Džamić (Belgrade)
- 13.45-14.05 **How to choose optimal sequence in the treatment of Renal Cell Carcinoma?**  
Uroš Bumbaširević, Belgrade, Serbia
- 14.05-14.25 **Triplets, doublets and novel trials in metastatic castration sensitive prostate cancer**  
Jeliazko Arabadjiev, Sofia, Bulgaria
- 14.25-14.45 **mCRPC: from biomarkers to radioisotopes,**  
Karima Oualla, Fes, Morocco
- 14.45-15.05 **How to optimize treatment in early stage urothelial cancer,**  
Gorana Matovina Brko, Novi Sad, Serbia
- 15.05-15.30 Discussion

● 15.30-16.15 SATELLITE SYMPOSIUM JANSSEN

● 16.15-16.45 SATELLITE SYMPOSIUM MERCK

16.45-17.15 Coffee Break

● 17.15-17.45 SATELLITE SYMPOSIUM SERVIER

- 17.45-19.00 **Gastrointestinal cancer**  
Chairman: Ivan Nikolic (Novi Sad), Nenad Mijalkovic (Belgrade),  
Zoran Radovanovic (Novi Sad)
- 17.45-18.05 **Treatment of elderly patients with colorectal cancer**  
Gabor Liposits, Herning, Denmark
- 18.05-18.25 **Colorectal cancer in young patient: Genetics, treatment and biomarkers**  
Neda Nikolic, Belgrade, Serbia
- 18.25-18.45 **Novel treatments for hepatocellular and cholangiocarcinoma**  
Radu Vidra, Cluj-Napoca, Romania
- 18.45-19.05 **Can we improve outcomes in pancreatic cancer?**  
Bogdan Bogdanovic, Novi Sad, Serbia
- 19.05-19.20 Discussion

### Sunday 3rd March

● 08.30-09.15 SATELLITE SYMPOSIUM LILLY

- 09.15-10.55 **Breast Cancer Session**  
Chairman: Ana Cvetanovic (Nis), Ljiljana Stamatovic (Belgrade),  
Ivana Bozovic-Spasojevic (Belgrade), Tanja Spanic (Slovenia)
- 09.15-09.35 **Antibody Drug Conjugates in Breast Cancer... how many HER we need?**  
Simona Borstnar, Ljubljana, Slovenia
- 09.35-09.55 **Optimal Sequencing in HR+/HER2- metastatic breast cancer**  
Matteo Lambertini, Genova Italy
- 09.55-10.15 **Novel Targets in Breast Cancer: Where to look at?**  
Kevin Punie, Wilrijk, Belgium
- 10.15-10.35 **How to de-escalate treatment in eBC?**  
Lazar Popovic, Novi Sad, Serbia
- 10.35-10.55 Discussion

● 11.00-11.45 SATELLITE SYMPOSIUM ROCHE

11.45-12.15 Coffee Break

● 12.15-13.00 SATELLITE SYMPOSIUM PFIZER

● 13.00-13.45 SATELLITE SYMPOSIUM NOVARTIS

13.45-14.30 Lunch break

### 14.30-15.15 Lung Cancer Session

- Chairman: Bojan Zaric (Novi Sad), Jelena Spasic (Belgrade),  
Marina Cekic (Nis)
- 14.30-14.45 **Optimal (neo)adjuvant therapy for resected lung cancer**  
Timur Cerić (Sarajevo, Bosnia and Herzegovina)
- 14.45-15.00 **Non-ALK, non-EGFR, non-CIT options in metastatic NSCLC. Novel biomarker guided therapies**  
Davorin Radosavljevic, Belgrade, Serbia
- 15.00-15.15 Discussion
- 15.15-16.00 **Young Oncologist Session: Problems in our countries and how to solve them together**  
Chairman: Jean-Pierre Lotz (FRA), Semir Beslija (B&H), Gorana Matovina Brko(SER)
- Kleida Mati, Albania  
Masa Jovicic, Serbia,  
Emir Sokolovic, B&H,  
Filip Stojanov, Bulgaria,
- 15.50-16.00 discussion

16.00 CLOSING



**13<sup>th</sup>**  
**NSOO**  
**March 1|3**  
**2024**

## **SATELITE SYMPOSIUM AGENDA**

### **SATELLITE SYMPOSIUM ASTRA ZENECA**

Friday 1<sup>st</sup> March, 18:30-19:15

#### **Unveiling the Destiny of EnHER2 Treatment**

ABC of ADCs

Ana Cvetanović, Nis, Serbia

Is HER2 a PanTumour target?

Lazar Popović, Novi Sad, Serbia

DESTINY Breast03

Matteo Lambertini, Genova, Italy

DESTINY Breast04

Ivana Božović - Spasojević, Belgrade, Serbia

### **SATELLITE SYMPOSIUM MEDISON PHARMA**

Saturday 2<sup>nd</sup> March, 08:30-09:00

#### **Metastatic uveal melanoma treatment options, tebentafusp**

Moderator: Lazar Popović, Novi Sad, Serbia

ImmTAC platform

Lidija Kandolf, Belgrade, Serbia

Tebentafusp 3-year overall survival in metastatic uveal melanoma

Nikolin Borislava, Novi Sad, Serbia

Treatment options in Uveal Melanoma

Suzana Matković, Belgrade, Serbia

### **SATELLITE SYMPOSIUM MSD**

Saturday 2<sup>nd</sup> March, 11:15-12:00

#### **The key to equality in treating malignant diseases**

Paradigm shift with immunotherapy in cancer treatment

Lazar Popović, Novi Sad, Serbia

Pembrolizumab in the treatment of metastatic and adjuvant melanoma

Suzana Matković, Belgrade, Serbia

Pembrolizumab in the treatment of metastatic NSCLC

Bojan Zarić, Novi Sad, Serbia

Pembrolizumab in the treatment of early and metastatic TNBC

Ivana Božović Spasojević, Belgrade, Serbia

Pembrolizumab in the treatment of RCC, cervical cancer and head and neck cancers

All participants

### **SATELLITE SYMPOSIUM AMICUS**

Saturday 2<sup>nd</sup> March, 12:0-12:45

#### **The Longest Follow up Results in RCC and Melanoma Clinical Trails**

The Evolution of RCC treatment

Zoran Džamić, Belgrade, Serbia

Dual IO – ASCO GU 2024 – New data

Lazar Popović, Novi Sad, Serbia

ESMO 2023 - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI)

in resected stage III/IV melanoma

Borislava Nikolin, Novi Sad, Serbia

Melanoma – The Longest mOS in melanoma treatment

Lidija Kandolf, Belgrade, Serbia

Discussion, Summary & Closure

### **SATELLITE SYMPOSIUM JANSSEN**

Saturday 2<sup>nd</sup> March, 15:30-16:15

#### **mHSPC treatment in Serbia: new chapter begins**

mHSPC treatment: ADT alone is not enough

Zoran Džamić, Belgrade, Serbia

Apalutamide in mHSPC: from clinical trial to real world evidence

Suzana Matković, Belgrade, Serbia

How to effectively sequence therapy in metastatic prostate cancer?

Lazar Popović, Novi Sad, Serbia

New chapter in mHSPC treatment: patients' profiles to benefit from apalutamide

Vesna Stojanović, Nis, Serbia

Discussion

### **SATELLITE SYMPOSIUM MERCK**

Saturday 2<sup>nd</sup> March, 16:15-16:45

#### **Oncology and beyond in lives changing through understanding and innovation**

Moderator of the meeting: Zoran Džamić, Belgrade, Serbia

20 Years of Legacy with Erbitux in the continuum of mCRC care

Biljana Kukić, Novi Sad, Serbia

Paradigm Shift in urothelial carcinoma management

Zoran Džamić, Belgrade, Serbia

Step forward with Bavencio in UC treatment

Maja Popović, Novi Sad, Serbia

Discussion

### **SATELLITE SYMPOSIUM SERVIER**

Saturday 2<sup>nd</sup> March, 17:15-17:45

#### **Advancing treatment strategies in gastrointestinal cancers**

Introduction

Zoran Radovanović, Novi Sad, Serbia

Further Extending the Continuum of Care in mCRC

Biljana Kukić, Novi Sad, Serbia

Novelties in mPDAC treatment guidelines

Ivan Nikolić, Novi Sad, Serbia

Conclusion by moderator

### **SATELLITE SYMPOSIUM LILLY**

Sunday 3<sup>rd</sup> March, 08:30-09:15

#### **How to identify patients with high risk in HR+HER2- early breast cancer who could benefit of addition of CDK4/6i**

Introduction

Lazar Popović, Novi Sad, Serbia

Heterogeneity of breast cancer and individual approach in the treatment of patients

Ivana Božović Spasojević, Belgrade, Serbia

Treatment guidelines for early HR+ /HER2- breast cancer

Ana Cvetanović, Nis, Serbia

Risk assessment in HR+ /HER2- patients with early breast cancer

Lazar Popović, Novi Sad, Serbia

CDK4/6i Similar but different

Ljiljana Stamatović, Belgrade, Serbia

Closing & Conclusions

Lazar Popović, Novi Sad, Serbia

### **SATELLITE SYMPOSIUM ROCHE**

Sunday 3<sup>rd</sup> March, 11:00-11:45

#### **A Role of pCR and Residual disease in eBC - The Best Way Forward**

Introduction

Lazar Popović, Novi Sad, Serbia

Case reports

Lazar Popović, Novi Sad, Serbia, Snjezana Tomic, Split, Croatia,

Marijana Milović Kovacević, Belgrade, Serbia, Ana Cvetanović, Nis, Serbia

Tips & Tricks

Snjezana Tomic, Split, Croatia

Conclusion

### **SATELLITE SYMPOSIUM PFIZER**

Sunday 3<sup>rd</sup> March, 12:15-13:00

#### **Stay tuned**

CDK4/6 inhibitors ... story to be continued

Lazar Popović, Novi Sad, Serbia

Value of talazoparib in clinical practice

Snježana Sušnjar, Belgrade, Serbia

The 'CROWN' in ALK kingdom

Bojan Zarić, Novi Sad, Serbia

### **SATELLITE SYMPOSIUM NOVARTIS**

Sunday 3<sup>rd</sup> March, 13:00-13:45

#### **Expanding Horizons in treatment of HR+ /HER2- Breast Cancer**

Reimagining treatment of HR+ /HER2- EBC

Ivana Božović - Spasojević, Belgrade, Serbia

Treatment adherence and tolerability in EBC

Gorana Matovina Brko, Novi Sad, Serbia

Efficacy, safety and QoL with ribociclib + ET in elderly patients with HR+ /HER2- ABC

Ivana Kolarov - Bjelobrč, Novi Sad, Serbia

Discussion